hERG Blockade by Iboga Alkaloids

详细信息    查看全文

• 作者：Kenneth Alper ; Rong Bai ; Nian Liu ; Steven J. Fowler…
• 关键词：Toxicology ; hERG ; Iboga alkaloid ; Ibogaine ; Noribogaine ; 18 ; Methoxycoronaridine (18 ; MC)
• 刊名：Cardiovascular Toxicology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：16
• 期：1
• 页码：14-22
• 全文大小：746 KB
• 参考文献：1.Bartlett, M. F., Dickel, D. F., & Taylor, W. I. (1958). The alkaloids of Tabernanthe-Iboga. Part VI. The Structures of ibogamine, ibogaine, tabernanthine and voacangine. Journal of the American Chemical Society, 80, 126–136.CrossRef
  2.Jana, G. K., Paul, S., & Sinha, S. (2011). Progress in the synthesis of iboga-alkaloids and their congeners. Organic Preparations and Procedures International, 43, 541–573.CrossRef
  3.Alper, K. R. (2001). Ibogaine: A review. The Alkaloids: Chemistry and Biology, 56, 1–38.PubMed
  4.Glick, S. D., Maisonneuve, I. M., & Szumlinski, K. K. (2001). Mechanisms of action of ibogaine: Relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. The Alkaloids: Chemistry and Biology, 56, 39–53.PubMed
  5.Alper, K. R., Lotsof, H. S., & Kaplan, C. D. (2008). The ibogaine medical subculture. Journal of Ethnopharmacology, 115, 9–24.CrossRef PubMed
  6.Vastag, B. (2005). Addiction research. Ibogaine therapy: A ‘vast, uncontrolled experiment’. Science, 308, 345–346.CrossRef PubMed
  7.Antonio, T., Childers, S. R., Rothman, R. B., Dersch, C. M., King, C., Kuehne, M., et al. (2013). Effect of iboga alkaloids on μ-opioid receptor-coupled G protein activation. PLoS ONE, 8, e77262.CrossRef PubMed PubMedCentral
  8.National Institutes of Health. (2014). IND-Enabling Studies and GMP Scale-Up of 18-Methoxycoronaridine Hydrochloride (18 MC) Project Number: 1U01DA034986-01. http://​projectreporter.​nih.​gov/​project_​info_​description.​cfm?​aid=​8448461&​icde=​16047111&​ddparam=​&​ddvalue=​&​ddsub=​&​cr=​41&​csb=​default&​cs=​ASC . Accessed January 05, 2015.
  9.Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology, 56, 155–171.PubMed
  10.Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions, 8, 234–242.CrossRef PubMed
  11.Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57, 398–412.CrossRef PubMed
  12.Hoelen, D. W., Spiering, W., & Valk, G. D. (2009). Long-QT syndrome induced by the antiaddiction drug ibogaine. New England Journal of Medicine, 360, 308–309.CrossRef PubMed
  13.Pleskovic, A., Gorjup, V., Brvar, M., & Kozelj, G. (2012). Ibogaine-associated ventricular tachyarrhythmias. Clinical Toxicology, 50, 157.CrossRef PubMed
  14.Dettmer, M. R., Cohn, B., & Schwarz, E. (2013). Prolonged QTc and ventricular tachycardia after ibogaine ingestion [(XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT)). Clinical Toxicology, 51, 285.
  15.Heling, D., Strassburg, C. P., & Wasmuth, J. C. (2014). Tod nach lbogain-Einnahme- Vergiftung durch Entgiftung (Death after ibogaine consumption—Intoxication by detoxification). Intensiv- und Notfallbehandlung, 39, 40–43.CrossRef
  16.Shawn, L. K., Alper, K., Desai, S. P., Stephenson, K., Olgun, A. M., Nelson, L. S., & Hoffman, R. S. (2012). Pause-dependent ventricular tachycardia and torsades de pointes after ibogaine ingestion [2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)]. Clinical Toxicology, 50, 654.
  17.Kannankeril, P., Roden, D. M., & Darbar, D. (2010). Drug-induced long QT syndrome. Pharmacological Reviews, 62, 760–781.CrossRef PubMed PubMedCentral
  18.Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440, 463–469.CrossRef PubMed
  19.Koenig, X., Kovar, M., Boehm, S., Sandtner, W., & Hilber, K. (2014). Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology, 19, 237–239.
  20.Thurner, P., Stary-Weinzinger, A., Gafar, H., Gawali, V. S., Kudlacek, O., Zezula, J., et al. (2014). Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine. Journal of Pharmacology and Experimental Therapeutics, 348, 346–358.
  21.Kontrimavičiūtė, V., Mathieu, O., Mathieu-Daudé, J. C., Vainauskas, P., Casper, T., Baccino, E., & Bressolle, F. M. (2006). Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. Journal of Analytical Toxicology, 30, 434–440.CrossRef PubMed
  22.Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274–292.CrossRef PubMed
  23.Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., et al. (2000). Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914, 394–401.CrossRef PubMed
  24.Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2014). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. The Journal of Clinical Pharmacology,. doi:10.​1002/​jcph.​1404 .PubMed
  25.Koenig, X., Kovar, M., Rubi, L., Mike, A. K., Lukacs, P., Gawali, V. S., et al. (2013). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug’s cardiac ion channel profile. Toxicology and Applied Pharmacology, 273, 259–268.CrossRef PubMed PubMedCentral
  26.Huang, X. P., Mangano, T., Hufeisen, S., Setola, V., & Roth, B. L. (2010). Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay and Drug Development Technologies, 8, 727–742.CrossRef PubMed PubMedCentral
  27.Roth, B. L. (2013). National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) assay protocol book version II. Chapel Hill, NC: Department of Pharmacology, University of North Carolina at Chapel Hill.
  28.Warrick, B., & Baltarowich, L. (2012). Ibogaine for opioid addiction: A deadly treatment [2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)]. Clinical Toxicology, 50, 656.
  29.Jalal, S., Daher, E., & Hilu, R. (2013). A case of death due to ibogaine use for heroin addiction: Case report. The American Journal on Addictions, 22, 302.CrossRef PubMed
  30.Roden, D. M. (1998). Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes. Pacing and Clinical Electrophysiology, 21, 1029–1034.CrossRef PubMed
  31.Cubeddu, L. X. (2009). Iatrogenic QT abnormalities and fatal arrhythmias: Mechanisms and clinical significance. Current Cardiology Reviews, 5, 166–176.CrossRef PubMed PubMedCentral
  32.Levin, K. H., Copersino, M. L., Epstein, D., Boyd, S. J., & Gorelick, D. A. (2008). Longitudinal ECG changes in cocaine users during extended abstinence. Drug and Alcohol Dependence, 95, 160–163.CrossRef PubMed PubMedCentral
  33.Otero-Anton, E., Gonzalez-Quintela, A., Saborido, J., Torre, J. A., Virgos, A., & Barrio, E. (1997). Prolongation of the QTc interval during alcohol withdrawal syndrome. Acta Cardiologica, 52, 285–294.PubMed
  34.Vlaanderen, L., Martial, L. C., Franssen, E. J. F., van der Voort, P. H. J., Oosterwerff, E., & Somsen, G. A. (2014). Cardiac arrest after ibogaine ingestion. Clinical Toxicology, 52, 642–643.CrossRef PubMed
  35.Dhahir, H. I. (1971). A comparative study on the toxicity of ibogaine and serotonin (p. 163). Bloomington: Indiana University.
  36.Glick, S. D., Maisonneuve, I. M., Hough, L. B., Kuehne, M. E., & Bandarage, U. K. (1999). (±)-18-Methoxycoronaridine: A novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Reviews, 5, 27–42.CrossRef
  37.Binienda, Z. K., Pereira, F., Alper, K., Slikker, W, Jr, & Ali, S. F. (2002). Adaptation to repeated cocaine administration in rats. Annals of the New York Academy of Sciences, 965, 172–179.CrossRef PubMed
  38.Schneider, J. A., & Rinehart, R. K. (1957). Analysis of the cardiovascular action of ibogaine hydrochloride. Archives Internationales de Pharmacodynamie et de Therapie, 110, 92–102.PubMed
  39.Mash, D. C., Allen-Ferdinand, K., Mayor, M., Kovera, C. A., Ayafor, J. F., Williams, I. C., et al. (1998). Ibogaine: Clinical observations of safety after single oral dose administrations. In Problems of drug dependence, 1998: Proceedings of the 60th annual scientific meeting, June 12–17 (p. 294). Scottsdale, Arizona: The College on Problems of Drug Dependence, Inc.
  40.Samorini, G. (1998). The initiation rite in the Bwiti Religion (Ndea Narizanga Sect, Gabon). Jahrbuch für Ethnomedizin und Bewusstseinsforschung, 6–7, 39–56.
  41.Alper, K., Reith, M. E. A., & Sershen, H. (2012). Ibogaine and the inhibition of acetylcholinesterase. Journal of Ethnopharmacology, 139, 879–882.CrossRef PubMed
  42.Kolecki, P. F., & Curry, S. C. (1997). Poisoning by sodium channel blocking agents. Critical Care Clinics, 13, 829–848.CrossRef PubMed
  43.Sanchez-Chapula, J. A., Navarro-Polanco, R. A., Culberson, C., Chen, J., & Sanguinetti, M. C. (2002). Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. Journal of Biological Chemistry, 277, 23587–23595.CrossRef PubMed
  44.Le Men, L., & Taylor, W. I. (1965). A uniform numbering system for indole alkaloids. Experientia, 21, 508–510.CrossRef PubMed
  45.Alper, K. R., & Cordell, G. A. (2001). A note concerning the numbering of the iboga alkaloids. In Ibogaine: Proceedings of the first international conference (also published as The Alkaloids Chemistry and Biology Vol. 56) (Alper, K. R., Glick, S. D., & Cordell, G. A., eds), pp. xxiii–xxiv. San Diego: Academic Press.
  46.Coi, A., Massarelli, I., Testai, L., Calderone, V., & Bianucci, A. M. (2008). Identification of “toxicophoric” features for predicting drug-induced QT interval prolongation. European Journal of Medicinal Chemistry, 43, 2479–2488.CrossRef PubMed
  47.Yan, G. X., Wu, Y., Liu, T., Wang, J., Marinchak, R. A., & Kowey, P. R. (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation, 103, 2851–2856.CrossRef PubMed
  48.Bai, R., Lu, J. G., Pu, L., Liu, N., Zhou, Q., Ruan, Y. F., et al. (2005). Left ventricular epicardial activation increases transmural dispersion of repolarization in healthy, long QT, and dilated cardiomyopathy dogs. PACE-Pacing Clinical Electrophysiology, 28, 1098–1106.CrossRef
  49.Wang, L., Lu, J., Zhang, F., Bai, R., & Wang, L. (2006). Effects of amiodarone on transmural dispersion of ventricular effective refractory periods across myocardial layers in the normal and hypertrophic canine heart. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 26, 182–184.CrossRef
  
• 作者单位：Kenneth Alper (1)
  Rong Bai (2)
  Nian Liu (2)
  Steven J. Fowler (3)
  Xi-Ping Huang (4)
  Silvia G. Priori (3)
  Yanfei Ruan (2) (3)
  
  1. Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, 10016, USA
  2. National Clinical Research Center for Cardiovascular Diseases and Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing, 100029, China
  3. Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, 10016, USA
  4. National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
  
• 刊物主题：Pharmacology/Toxicology; Cardiology;
• 出版者：Springer US
• ISSN：1559-0259

文摘

The iboga alkaloids are a class of naturally occurring and synthetic compounds, some of which modify drug self-administration and withdrawal in humans and preclinical models. Ibogaine, the prototypic iboga alkaloid that is utilized clinically to treat addictions, has been associated with QT prolongation, torsades de pointes and fatalities. hERG blockade as IKr was measured using the whole-cell patch clamp technique in HEK 293 cells. This yielded the following IC₅₀ values: ibogaine manufactured by semisynthesis via voacangine (4.09 ± 0.69 µM) or by extraction from T. iboga (3.53 ± 0.16 µM); ibogaine’s principal metabolite noribogaine (2.86 ± 0.68 µM); and voacangine (2.25 ± 0.34 µM). In contrast, the IC₅₀ of 18-methoxycoronaridine, a product of rational synthesis and current focus of drug development was >50 µM. hERG blockade was voltage dependent for all of the compounds, consistent with low-affinity blockade. hERG channel binding affinities (K _i) for the entire set of compounds, including 18-MC, ranged from 0.71 to 3.89 µM, suggesting that 18-MC binds to the hERG channel with affinity similar to the other compounds, but the interaction produces substantially less hERG blockade. In view of the extended half-life of noribogaine, these results may relate to observations of persistent QT prolongation and cardiac arrhythmia at delayed intervals of days following ibogaine ingestion. The apparent structure–activity relationships regarding positions of substitutions on the ibogamine skeleton suggest that the iboga alkaloids might provide an informative paradigm for investigation of the structural biology of the hERG channel. Keywords Toxicology hERG Iboga alkaloid Ibogaine Noribogaine 18-Methoxycoronaridine (18-MC)